PE Anti-MIP-1 alpha/CCL3 + CCL3L1 antibody [EPR22529-19],Abcam,AB317071

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Host

Rabbit

Reactivity

Human, Human, Mouse

Application

Flow Cyt (Intra), ICC/IF

Conjugate

PE

Platform ID

BAB177314142

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NamePE Anti-MIP-1 alpha/CCL3 + CCL3L1 antibody [EPR22529-19]
Cat. No.AB317071
HostRabbit
IsotypeIgG
ReactivityHuman, Human, Mouse
ConjugationPE
ApplicationFlow Cyt (Intra), ICC/IF
ClonalityMonoclonal
Clone NumberEPR22529-19
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.4 Preservative: 0.02% Sodium azide Constituents: PBS, 1% BSA
Storage+4°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Monokine with inflammatory and chemokinetic properties. Binds to CCR1, CCR4 and CCR5. One of the major HIV-suppressive factors produced by CD8+ T-cells. Recombinant MIP-1-alpha induces a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV). See full target information CCL3

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.